OTCMKTS:RDGL Advanced Medical Isotope Q4 2025 Earnings Report $0.05 0.00 (-6.00%) As of 09:48 AM Eastern ProfileEarnings History Advanced Medical Isotope EPS ResultsActual EPS-$0.01Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAdvanced Medical Isotope Revenue ResultsActual Revenue$0.02 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAdvanced Medical Isotope Announcement DetailsQuarterQ4 2025Date3/30/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Advanced Medical Isotope Earnings HeadlinesVivos Inc. Announces Peer-Reviewed Publication Characterizing PrecisionGel™ Polymer Platform in Elsevier Journal of Drug Delivery Science and TechnologySeptember 3, 2026 | globenewswire.comVivos Inc. Achieves Two Major Operational Milestones: First IsoPet® Shipments from New U.S. Production Facility and Authorization from India's Nuclear Regulatory Authority for International Manufacturing CenterAugust 18, 2026 | globenewswire.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 2 at 1:00 AM | Altimetry (Ad)Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update - CorrectionJuly 27, 2026 | globenewswire.comVivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate UpdateJuly 27, 2026 | globenewswire.comVivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™July 6, 2026 | globenewswire.comSee More Advanced Medical Isotope Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Advanced Medical Isotope? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Advanced Medical Isotope and other key companies, straight to your email. Email Address About Advanced Medical IsotopeAdvanced Medical Isotope (OTCMKTS:RDGL) is a medical technology company developing targeted radiation products for cancer treatment. Its primary product candidate is RadioGel™, an injectable brachytherapy device designed to deliver yttrium-90 radiation directly to solid tumors. The company’s approach is intended to provide localized treatment while limiting radiation exposure to surrounding healthy tissue. RadioGel is being developed for potential use in treating tumors that may be difficult to address with conventional external-beam radiation or surgery. The company has focused on advancing the product through research, regulatory development and clinical evaluation, although its product candidates remain subject to applicable regulatory approvals and clinical requirements. Advanced Medical Isotope is based in the United States and has historically concentrated on the development of radioisotope-based therapies rather than operating a broad commercial healthcare services business. Publicly available information about its commercial operations, geographic reach and current leadership is limited.View Advanced Medical Isotope ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
